News for LXXGF Stock

LexaGene Files for Chapter 7 Bankruptcy LexaGene Provides Update on BioPharma Sector LexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing Additional Interest from BioPharma Customers BioPharma Engages LexaGene in Second Feasibility Study LexaGene Holdings Proposes to Amend Warrants Terms LexaGene Successfully Completes Statement of Work for BioPharma Company LexaGene Closes Secured Convertible Note Transaction Large Biopharma Company Engages LexaGene in Statement of Work to Expedite Technology Validation LexaGene Receives Signed Quote from Large Biopharma Company to Purchase a MiQLab System LexaGene Announces MiQLab® System Sale to Veterinary Hospital in California LexaGene Verifies CDC Monkeypox Assay Works on MiQLab System and Readies Company Should an EUA be Declared LexaGene’s MiQLab System Generates Leptospira Results in as Soon as 30 minutes using Isothermal Chemistry University of Pennsylvania’s School of Veterinary Medicine to Evaluate New Gastrointestinal Panel Using LexaGene’s MiQLab System LexaGene Reduces Time-to-Result by ~35% LexaGene Announces Filing of Financial Statements, Revocation of MCTO & the Granting of Incentive Equity Awards to Employees LexaGene Completes Multi-Center Validation Study Using MiQLab® System for Diagnosing Urinary Tract Infections LexaGene Provides MCTO Update LexaGene Announces Webinar by UC Davis Professor on Use of MiQLab® System for Diagnosis of Urinary Tract Infections LexaGene Announces MiQLab® System Sale to Veterinary Hospital in Wisconsin LexaGene Announces Management Cease Trade Order LexaGene Files Form 10 Registration Statement with the SEC and Announces a Delay in Filing Year-End Annual Canadian Financial Filings LexaGene Announces Multi-System Purchase from a Large Market Leader in Animal Health LexaGene Successfully Completes CRADA with US Army LexaGene Announces Multi-System Purchase from a Corporate Veterinary Reference Laboratory LexaGene Announces Results of Annual General and Special Meeting LexaGene Closes Multiple MiQLab Sales LexaGene Intends to Pursue Full Panel Pathogen Testing through the FDA Leading Veterinary Academic, Dr. Jane Sykes, Joins LexaGene Board of Directors LexaGene Expands Bio-Pharma Contamination Panel by Adding Test that includes a Biothreat Agent LexaGene Receives 2021 BioTech Breakthrough Award LexaGene Finalizes Design of Pneumonia Panel LexaGene Completes First Stage of U.S. ARMY DEVCOM Agreement LexaGene’s MiQLab™ System Selected to be a Best in Show Spotlight at the 47th Annual Industry Petcare Innovation Summit LexaGene to Host Corporate Update on November 3 LexaGene Completes Analytical Studies for FDA EUA of COVID-19 Testing LexaGene’s Largest Study Validates Accuracy of its Veterinary Test Panel LexaGene to Webcast Live at VirtualInvestorConferences.com October 7th LexaGene Expands Brand Awareness at Key Investor Conferences LexaGene Reports on Recent Veterinary Trade Shows LexaGene Enters into Cooperative Research and Development Agreement with the United States Army’s Combat Capabilities Development Command LexaGene’s MiQLab™ Accurately Detects Multiple Strains of Pathogenic Bacteria in Polymicrobial Samples Compared to Conventional Culture LexaGene’s MiQLab™ System Featured at Three Key Veterinary Tradeshows LexaGene to Present at the SNN Network Summer Virtual Event on Thursday, August 19, 2021 LexaGene Demonstrates a Simple and Inexpensive Multiplex PCR Chemistry with Shorter Lead Times for use on its MiQLab System LexaGene’s MiQLab Detects Common Bioreactor Contaminant up to 300 Times Faster than Conventional Methods LexaGene Engages LaVoieHealthScience as Integrated Investor and Public Relations Agency of Record New Sale of LexaGene’s MiQLab™ System Propels Early Diagnostic Testing in Veterinarian Practices LexaGene’s MiQLab Offers Rapid Plague Detection for Bioterrorism Threats LexaGene Closes Sale to Alpine Veterinary Hospital LexaGene detects a slow-growing bacterium at least 36-times faster than conventional methods with the potential to increase vaccine safety and supply LexaGene Sells a MiQLab System to Denver Animal Emergency LexaGene Partners with Ethos Discovery to Develop New Companion Animal Diagnostic Tests LexaGene Takes Steps to List on the Nasdaq LexaGene Expands its Sales Team LexaGene Hosts a Seminar to Present MiQLab Data from Veterinary Samples LexaGene’s Provides Corporate Update LexaGene Receives $3.6M from the Exercise of Warrants LexaGene Announces Change in Management and Appoints New Member to the Board of Directors LexaGene’s MiQLab Successfully Detects Mutant UK and South African COVID-19 Sequences LexaGene Provides a Corporate Update